Peptides Studied for Injury Recovery: What the Evidence Shows

Search for "best peptides for injury recovery" and you will find confident lists. The research behind those lists is much thinner than the confidence suggests. Most of it comes from rats, mice and cell cultures. The human data that exist are small, often uncontrolled, and mostly about skin wounds rather than tendons, ligaments or muscles.

This guide covers the compounds most often discussed for healing. For each one we give what it is, the strongest level of evidence we could find, and one or two findings sourced to PubMed. We order them by the strength of that evidence, not by how well they might work. None of this is a recommendation.

How to read the evidence levels

• Human RCT: a randomized controlled trial in people, with a comparison group. The strongest level here, though every trial below is small.
• Human observational: people were studied, but without a proper control group, so placebo effects and natural recovery can't be ruled out.
• Animal / in vitro: preclinical work in animals (in vivo) or cells (in vitro). Useful for ideas, poor at predicting results in people.

Summary table

LL-37

What it is. A human antimicrobial peptide made by skin and immune cells. See the LL-37 page.

Strongest evidence: small human RCTs, in chronic wounds. In a first-in-human trial of 34 people with hard-to-heal venous leg ulcers, twice-weekly topical LL-37 at the two lower concentrations tested reduced mean ulcer area by 68% and 50%, while the highest concentration did no better than placebo (Grönberg 2014). A later double-blind trial in diabetic foot ulcers reported a consistently greater increase in the granulation index (a measure of the new tissue that fills a wound) with LL-37 cream than with placebo over four weeks (Miranda 2023).

The gap. These are skin ulcers treated topically. They say nothing about injected LL-37 or about sports injuries.

Thymosin beta-4 and TB-500

What they are. Thymosin beta-4 (Tβ4) is a natural 43-amino-acid protein involved in cell movement and repair. "TB-500" is a product name, not a defined drug. A doping-control lab analysing a TB-500 product identified in it an acetylated seven-amino-acid fragment of Tβ4 (Ac-LKKTETQ) (Esposito 2012). See the TB-500 page.

Strongest evidence: a phase 2 human trial, of full-length Tβ4 applied to skin. In a double-blind, placebo-controlled study of 73 patients with venous ulcers across eight European sites, safety was comparable to placebo. The authors wrote that a 0.03% dose "may have the potential" to speed healing, with complete healing within 3 months in about 25% of patients (Guarnera 2010). That is a hedged conclusion, not a clear win.

Animal data. In diabetic and aged mice, Tβ4 increased wound contraction and collagen deposition, and the seven-amino-acid actin-binding fragment worked comparably in aged mice (Philp 2003).

The gap. We found no controlled human trial of injected TB-500 for any injury.

GHK-Cu

What it is. A naturally occurring three-amino-acid peptide bound to copper. See the GHK-Cu page.

Strongest evidence: small human RCTs, mostly negative on objective measures. In 13 patients randomized to skin care with or without GHK-Cu after CO2 laser resurfacing, blinded evaluation found no difference in redness, wrinkles or overall skin quality; only patient satisfaction was higher with GHK-Cu (Miller 2006). An older trial in 86 patients with venous stasis ulcers found a "tripeptide copper complex" cream no better than placebo (Bishop 1992). That abstract does not name the tripeptide, so it cannot be confirmed from the abstract alone that it was GHK-Cu.

Animal data. In rat wound chambers, GHK-Cu increased collagen and other connective-tissue components in a concentration-dependent way (Maquart 1993).

Compare it with BPC-157 in GHK-Cu vs BPC-157.

BPC-157

What it is. A synthetic 15-amino-acid peptide based on a sequence from a protein in human gastric juice. It is sold as a research chemical, not an approved drug. See the BPC-157 page.

Strongest evidence: uncontrolled human reports. A 2025 systematic review of BPC-157 in orthopaedic sports medicine included 36 studies: 35 preclinical and 1 clinical. That one clinical study was a retrospective review in which 7 of 12 patients reported knee-pain relief lasting more than 6 months. The review found no clinical safety data (Vasireddi 2025). The underlying study was a retrospective chart review of treated patients, followed up by phone, with no standard tools to measure function (Lee 2021).

Animal and cell data. In rat tendon cells, BPC-157 increased tendon-fibroblast outgrowth, survival under oxidative stress, and migration (Chang 2011).

BPC-157 is often paired with TB-500; see BPC-157 vs TB-500 and the Wolverine Stack. Those combinations have not been tested in controlled human trials.

MGF (Mechano Growth Factor)

What it is. A name for a splice variant of the IGF-1 gene that muscle switches on after loading or damage, and for a synthetic 24-amino-acid peptide sold under the same name. See the MGF page.

Strongest evidence: human gene-expression data, not treatment trials. After a bout of heavy knee-extension exercise, MGF messenger RNA rose in the thigh muscle of younger adults but not of adults aged 70 to 82 (Hameed 2003). That measures what the body makes, not what an injected peptide does.

The gap. A review noted that no natural MGF peptide has actually been isolated from cells, tissues or body fluids, and that the synthetic peptide's actions should be kept distinct from the gene's (Matheny 2010).

KPV

What it is. A three-amino-acid fragment (Lys-Pro-Val) of alpha-MSH, a hormone with anti-inflammatory effects. See the KPV page.

Strongest evidence: mouse studies of gut inflammation. Oral KPV reduced chemically induced colitis in mice, and in cell studies it entered cells through the PepT1 transporter (Dalmasso 2008). A second group found faster recovery and less inflammation in two mouse colitis models (Kannengiesser 2008).

The gap. We found no human trials, and no studies of KPV in muscle, tendon or joint injury. Its place in "recovery" blends such as KLOW rests on this animal gut work.

The bottom line

The only randomized human data on this list concern topical treatment of chronic skin ulcers, and even there the trials are small and the results mixed. For the musculoskeletal injuries most people have in mind, the evidence is almost entirely animal work plus one small, uncontrolled chart review. That does not prove these compounds fail. It means the question has not been properly tested in people.

Sources

• Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair Regen, 2014. PMID 25041740
• Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcer: a randomized double-blind controlled trial. Arch Dermatol Res, 2023. PMID 37480520
• Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal, 2012. PMID 22962027
• The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci, 2010. PMID 20536470
• Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen, 2003. PMID 12581423
• Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg, 2006. PMID 16847171
• A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg, 1992. PMID 1495150
• In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest, 1993. PMID 8227353
• Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J, 2025. PMID 40756949
• Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med, 2021. PMID 34324435
• The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985), 2011. PMID 21030672
• Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise. J Physiol, 2003. PMID 12562960
• Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. Endocrinology, 2010. PMID 20130113
• PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 2008. PMID 18061177
• Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis, 2008. PMID 18092346

This article is for educational and research purposes only and is not medical advice.